BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35441343)

  • 1. Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab.
    Zhang X; Liu Q; Zhang H; Tan C; Zhu Q; Chen S; Du Y; Yang H; Li Q; Xu C; Wu C; Wang QK
    Mol Genet Genomics; 2022 May; 297(3):833-841. PubMed ID: 35441343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.
    Shirahama R; Ono T; Nagamatsu S; Sueta D; Takashio S; Chitose T; Fujisue K; Sakamoto K; Yamamoto E; Izumiya Y; Kaikita K; Hokimoto S; Hori M; Harada-Shiba M; Kajiwara I; Ogawa H; Tsujita K
    Intern Med; 2018; 57(24):3551-3557. PubMed ID: 30555118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Durst R; Ibe UK; Shpitzen S; Schurr D; Eliav O; Futema M; Whittall R; Szalat A; Meiner V; Knobler H; Gavish D; Henkin Y; Ellis A; Rubinstein A; Harats D; Bitzur R; Hershkovitz B; Humphries SE; Leitersdorf E
    Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
    Liu Y; Han B
    Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia.
    Hu H; Chen R; Hu Y; Wang J; Lin S; Chen X
    Lipids Health Dis; 2021 Sep; 20(1):101. PubMed ID: 34511120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.
    Pisciotta L; Priore Oliva C; Cefalù AB; Noto D; Bellocchio A; Fresa R; Cantafora A; Patel D; Averna M; Tarugi P; Calandra S; Bertolini S
    Atherosclerosis; 2006 Jun; 186(2):433-40. PubMed ID: 16183066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia.
    Lv X; Wang C; Liu L; Yin G; Zhang W; Abdu FA; Shi T; Zhang Q; Che W
    Lipids Health Dis; 2023 Oct; 22(1):175. PubMed ID: 37853441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Deep Intronic Variant in LDLR in Familial Hypercholesterolemia.
    Reeskamp LF; Hartgers ML; Peter J; Dallinga-Thie GM; Zuurbier L; Defesche JC; Grefhorst A; Hovingh GK
    Circ Genom Precis Med; 2018 Dec; 11(12):e002385. PubMed ID: 30562117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel LDLR p.Glu179Met variant in Thai families with familial hypercholesterolemia and response to treatment with PCSK9 inhibitor.
    Pussadhamma B; Wongvipaporn C; Wutthimanop A; Nuinoon M; Porntadavity S; Jeenduang N
    Sci Rep; 2024 Mar; 14(1):6785. PubMed ID: 38514665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review.
    Mohd Nor NS; Al-Khateeb AM; Chua YA; Mohd Kasim NA; Mohd Nawawi H
    BMC Pediatr; 2019 Apr; 19(1):106. PubMed ID: 30975109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.
    Pisciotta L; Fasano T; Bellocchio A; Bocchi L; Sallo R; Fresa R; Colangeli I; Cantafora A; Calandra S; Bertolini S
    Atherosclerosis; 2007 Oct; 194(2):e116-22. PubMed ID: 17140581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
    Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India.
    Reddy LL; Shah SAV; Ponde CK; Dalal JJ; Jatale RG; Dalal RJ; Rajani RM; Pillai SK; Vanjani CV; Ashavaid TF
    J Hum Genet; 2021 Oct; 66(10):983-993. PubMed ID: 33864011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.
    Michikura M; Hori M; Ogura M; Hosoda K; Harada-Shiba M
    Atherosclerosis; 2022 Oct; 358():41-46. PubMed ID: 36087353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Chinese homozygote of familial hypercholesterolemia: identification of a novel C263R mutation in the LDL receptor gene.
    Wang D; Wu B; Li Y; Heng W; Zhong H; Mu Y; Wang J
    J Hum Genet; 2001; 46(3):152-4. PubMed ID: 11310584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
    Ruel I; Aljenedil S; Sadri I; de Varennes É; Hegele RA; Couture P; Bergeron J; Wanneh E; Baass A; Dufour R; Gaudet D; Brisson D; Brunham LR; Francis GA; Cermakova L; Brophy JM; Ryomoto A; Mancini GBJ; Genest J
    Clin Chem; 2018 Feb; 64(2):355-362. PubMed ID: 29038147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.